Radiolabelled Somatostatin Analogues for Single-photon Emission Scintigraphy

E Nowosinska, JR Buscombe

Hong Kong J Radiol 2010;13:175-80

One of the areas where nuclear medicine has proved effective has been in the imaging of somatostatin receptor expressing tumours. These can be overexpressed in a number of tumours, but are most commonly seen in a family of

tumours called neuroendocrine tumours. The ability to visualise a particular tumour site depends on the affinity of the radiopeptide for the somatostatin receptors expressed by that tumour. The most widely used such peptide is Indium-111 (111In)-pentetreotide, which is commercially available in many countries. It is possible to change the peptide chain to affect affinities to tumours, but no other 111Indium-labelled agent has become more widely used, partly due to costs. More recent work has concentrated on technetium-99m (99mTc)-labelled tracers including 99mTechnetium-depreotide used for lung cancer imaging and 99mTechnetium-EDDA/HYNIC-octreotate, which combines optimal tumour affinity and imaging characteristics.

中文摘要

單光子發射閃爍照相法的放射標記生長抑素類似物

E Nowosinska、JR Buscombe

核醫學被證實為有效的一個應用是對腫瘤組織生長抑素受體的成像。這種受體在許多腫瘤會過度表達，但這種情況發生在神經內分泌腫瘤尤其普遍。至於是否可以觀察到一個特定的腫瘤位置，則視乎放射標記的多曲肽對於該腫瘤組織生長抑素受體的親和力。由於腫瘤顯像劑111Indium-pentetreotide在多個國家的市場上都可買到，所以被廣泛使用。事實上，可以更改肽鏈來改變標記物對其他腫瘤的親和力，可是因為成本關係，沒有其他111Indium標記物普及應用。最近有研究集中在99mTc標記放射性示踪劑，包括針對肺癌成像的99mTechnetium-depreotide和99mTechnetium-EDDA/HYNIC-octreotate，後者結合了最佳的腫瘤的親和力和影像特性。活檢。